Abivax SA (Euronext PARIS:FR0012333284 – ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the successful completion of its positive pre-New Drug Application (NDA) interaction with the U.S. Food and Drug Administration (FDA) for obefazimod for the treatment of adults with moderately to severely active ulcerative colitis (UC). Constructive FDA feedback resulted in alignment on the Company's planned NDA submission strategy and supported the planned content and format of the NDA submission. Abivax remains on track to submit its first NDA for obefazimod by the end of 2026.